Skip to content

Gut microbial activity, lifestyle factors, and bone metabolism in premenopausal and postmenopausal women

Gut microbial activity, lifestyle factors, and bone metabolism in premenopausal and postmenopausal women

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN17635288
Enrollment
42
Registered
2026-05-29
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis Musculoskeletal Diseases

Interventions

A total of 42 participants will be recruited into the study, with 21 premenopausal women (aged 18–40 years) and 21 postmenopausal women (=5 years post-menopause, aged 60 years and older). Each partici

Sponsors

Imperial College London
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Premenopausal women aged 18-40 years 2. Postmenopausal women (=5 years post menopause) aged 60 years and older 3. Healthy individuals without chronic diseases or conditions that significantly impact the gut microbiome, metabolism, or bone health (e.g., diabetes, inflammatory bowel disease, etc.) 4. HbA1c <48 mmol/mol 5. Individuals with a BMI between 18.5 and 30 kg/m² (normal weight to overweight)

Exclusion criteria

Exclusion criteria: 1. Non-English speakers 2. Individuals with chronic diseases that affect the gut microbiome, metabolic health or bone metabolism (e.g. type 1 or 2 diabetes, bowel diseases such as Crohn’s disease or irritable bowel syndrome, osteoporosis, etc) 3. HbA1c =48 mmol/mol 4. Individuals with a BMI less than 18.5 kg/m² (underweight) or greater than 30 kg/m² (obesity) 5. Medications and dietary supplements in the last 3 months that would impact trial outcomes: 5.1. Antibiotics 5.2. Proton Pump Inhibitors (PPIs) 5.3. Laxatives & Antidiarrheals 5.4. Immunosuppressants 5.5. Metformin 5.6. Nonsteroidal anti-inflammatory drugs 5.7. Bisphosphonates 5.8. Estrogen and/or progesterone (Hormone replacement therapy (HRT)) 5.9. Denosumab 5.10. Anabolic steroids 5.11. Teriparatide 5.12. Thyroid medication 5.13. Dietary fibre, prebiotic or probiotic supplements 6. Known congenital or acquired bone disease other than osteopenia (including osteomalacia, hyperparathyroidism, Paget’s disease) 7. History of major psychiatric illness 8. Drink more than 14 units of alcohol per week on a regular basis 9. Consumption of recreational drugs 10. Current smokers (daily) 11. Pregnancy 12. Not involved in other research projects in the previous 12 weeks

Countries

England, United Kingdom

Contacts

Public ContactEdward Chambers
e.chambers@imperial.ac.uk+44 (0)7786361040

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 11, 2026